May 11, 2017 / 9:33 PM / 4 months ago

BRIEF-Atossa Genetics qtrly loss per basic common share $0.45

May 11 (Reuters) - Atossa Genetics Inc:

* Qtrly loss per basic common share $0.45

* “we are in the research and development phase and do not generate revenue”

* Plans to commence a phase 2 clinical study of endoxifen in second half of 2017 Source text (bit.ly/2qYPv5E) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below